Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.

Current cancer drug targets - 1 May 2012

Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A

Abstract excerpt

Over the past two decades, progresses in colorectal cancer treatment have significantly improved patient survival and quality of life. However, unresectable metastatic colorectal cancer remains virtually incurable, making the search for new effective therapeutics mandatory. An important limitation to the development of new agents has been the difficulty to exploit mutated tumor suppressors or "undruggable"...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoma
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Proto-Oncogene Proteins c-myc

Share to Wnt Signaling Pathway

Source

Identifiers

PMID: 22385509
DOI: 10.2174/156800912800190938

Genes

BRCA1
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.PMID 22385509Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Semantic proximity Read ↗

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.Semantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

Drugging the Cancers Addicted to DNA RepairSemantic proximity Read ↗

DNA repair in cancer: emerging targets for personalized therapySemantic proximity Read ↗

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.Semantic proximity Read ↗

Targeting the DNA damage response in oncologySemantic proximity Read ↗

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinicSemantic proximity Read ↗

PARP inhibitors: Synthetic lethality in the clinicSemantic proximity Read ↗

Development of synthetic lethality anticancer therapeutics.Semantic proximity Read ↗

BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethalitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.